Emzor Pharmaceuticals Industrial Limited, one of the companies implicated in the illegal manufacture and distribution of codeine-contained syrup has resumed operations.
Speaking during a press conference in Lagos on Sunday, Uzoma Ezeoke, an executive director at the company, said: We are happy to announce that after carrying out all necessary due diligence, NAFDAC has now reopened the factory.
He also noted that it was quite unfortunate for the company to be featured in the list of companies responsible for illegal manufacture and distribution of codeine-contained syrup
“Unfortunately, we found ourselves as a key selling point for that documentary. All eyes were on us even when others were mentioned,” He stated.
The firm’s Group Managing Director and Chief Executive Officer (CEO), Dr. Stella Okoli, expressed pain that one of its products – Emzolyn with Codeine, a therapeutic product, made for the relief of a specific illness, has been turned into a substance of abuse.
She added that the menace of drug abuse is a national concern and everybody should be concerned, adding that all hands should be on deck to arrest the situation.
She said her company, Emzor, would seek to make relevant and impactful contributions to the multi-agency discussions on the way forward, especially from the limited depiction of rehabilitation efforts represented in the BBC programme.
“As a parent and especially a mother, I am deeply saddened by the problem of drug abuse and its damaging effect on our children and youths. We follow good manufacturing practice (GMP) here at Emzor, and NAFDAC officials from the investigation and enforcement directorate conducted an inspection of our factory and were given full access to all the records they requested. We are happy to announce that after carrying out all necessary due diligence, NAFDAC has now reopened the factory,” said Okoli.
Copyright 2018 E247Magazine. Permission to use quotations from this article is granted subject to appropriate credit being given to https://www.e247mag.com as the source.